Supernus Pharmaceuticals annual ebitda margin
2010
2011
2012
2013
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
2024
2025
Supernus Pharmaceuticals EBITDA Margin Growth & History (SUPN)
Supernus Pharmaceuticals's ebitda margin was 4.07% for fiscal 2025.
View full Supernus Pharmaceuticals company overviewSupernus Pharmaceuticals annual ebitda margin history
| Fiscal year | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| 2025 | 2025-12-31 | 4.07% | −20.42 pp |
| 2024 | 2024-12-31 | 24.49% | +11.39 pp |
| 2023 | 2023-12-31 | 13.10% | −6.63 pp |
| 2022 | 2022-12-31 | 19.73% | −0.73 pp |
| 2021 | 2021-12-31 | 20.46% | −16.40 pp |
| 2020 | 2020-12-31 | 36.86% | −2.66 pp |
| 2019 | 2019-12-31 | 39.52% | +2.47 pp |
| 2018 | 2018-12-31 | 37.05% | +1.43 pp |
| 2017 | 2017-12-31 | 35.63% | +9.29 pp |
| 2016 | 2016-12-31 | 26.33% | +11.57 pp |
| 2015 | 2015-12-31 | 14.76% | +19.45 pp |
| 2014 | 2014-12-31 | −4.69% | +504.32 pp |
| 2013 | 2013-12-31 | −509.01% | +2281.39 pp |
| 2012 | 2012-12-31 | −2,790.41% | +1801.50 pp |
| 2011 | 2011-12-31 | −4,591.91% | +32139.23 pp |
| 2010 | 2010-12-31 | −36,731.13% | — |
Supernus Pharmaceuticals quarterly ebitda margin
Q2.11
Q3.11
Q4.11
Q1.12
Q2.12
Q3.12
Q4.12
Q1.13
Q2.13
Q3.13
Q4.13
Q1.14
Q2.14
Q3.14
Q4.14
Q1.15
Q2.15
Q3.15
Q4.15
Q1.16
Q2.16
Q3.16
Q4.16
Q1.17
Q2.17
Q3.17
Q4.17
Q1.18
Q2.18
Q3.18
Q4.18
Q1.19
Q2.19
Q3.19
Q4.19
Q1.20
Q2.20
Q3.20
Q4.20
Q1.21
Q2.21
Q3.21
Q4.21
Q1.22
Q2.22
Q3.22
Q4.22
Q1.23
Q2.23
Q3.23
Q4.23
Q1.24
Q2.24
Q3.24
Q4.24
Q1.25
Q2.25
Q3.25
Q4.25
Q1.26
Q2.26
| Fiscal quarter | Period ended | EBITDA margin | Change (percentage points) |
|---|---|---|---|
| Q2 2026 | 2026-06-30 | −26.28% | −33.92 pp |
| Q1 2026 | 2026-03-31 | 8.57% | +1.81 pp |
| Q4 2025 | 2025-12-31 | 31.31% | −14.55 pp |
| Q3 2025 | 2025-09-30 | −31.09% | −54.68 pp |
| Q2 2025 | 2025-06-30 | 7.64% | −6.12 pp |
| Q1 2025 | 2025-03-31 | 6.76% | −5.49 pp |
| Q4 2024 | 2024-12-31 | 45.86% | +8.09 pp |
| Q3 2024 | 2024-09-30 | 23.59% | +17.91 pp |
| Q2 2024 | 2024-06-30 | 13.76% | +26.30 pp |
| Q1 2024 | 2024-03-31 | 12.25% | −4.51 pp |
| Q4 2023 | 2023-12-31 | 37.77% | −20.21 pp |
| Q3 2023 | 2023-09-30 | 5.68% | +6.09 pp |
| Q2 2023 | 2023-06-30 | −12.53% | −19.61 pp |
| Q1 2023 | 2023-03-31 | 16.76% | +1.47 pp |
| Q4 2022 | 2022-12-31 | 57.98% | +38.61 pp |
| Q3 2022 | 2022-09-30 | −0.41% | −22.77 pp |
| Q2 2022 | 2022-06-30 | 7.08% | −17.55 pp |
| Q1 2022 | 2022-03-31 | 15.30% | +0.17 pp |
| Q4 2021 | 2021-12-31 | 19.37% | −21.11 pp |
| Q3 2021 | 2021-09-30 | 22.37% | −14.27 pp |
| Q2 2021 | 2021-06-30 | 24.63% | −11.78 pp |
| Q1 2021 | 2021-03-31 | 15.13% | −17.24 pp |
| Q4 2020 | 2020-12-31 | 40.48% | −4.32 pp |
| Q3 2020 | 2020-09-30 | 36.64% | −2.65 pp |
| Q2 2020 | 2020-06-30 | 36.41% | −4.66 pp |
| Q1 2020 | 2020-03-31 | 32.37% | +0.66 pp |
| Q4 2019 | 2019-12-31 | 44.80% | +6.75 pp |
| Q3 2019 | 2019-09-30 | 39.29% | +2.32 pp |
| Q2 2019 | 2019-06-30 | 41.07% | +4.68 pp |
| Q1 2019 | 2019-03-31 | 31.71% | −4.89 pp |
| Q4 2018 | 2018-12-31 | 38.05% | −8.47 pp |
| Q3 2018 | 2018-09-30 | 36.97% | +8.81 pp |
| Q2 2018 | 2018-06-30 | 36.39% | +1.62 pp |
| Q1 2018 | 2018-03-31 | 36.60% | +6.16 pp |
| Q4 2017 | 2017-12-31 | 46.51% | +18.19 pp |
| Q3 2017 | 2017-09-30 | 28.16% | −7.29 pp |
| Q2 2017 | 2017-06-30 | 34.77% | +11.63 pp |
| Q1 2017 | 2017-03-31 | 30.44% | +14.91 pp |
| Q4 2016 | 2016-12-31 | 28.32% | +9.49 pp |
| Q3 2016 | 2016-09-30 | 35.45% | +22.02 pp |
| Q2 2016 | 2016-06-30 | 23.14% | +11.91 pp |
| Q1 2016 | 2016-03-31 | 15.54% | +0.75 pp |
| Q4 2015 | 2015-12-31 | 18.83% | +1.52 pp |
| Q3 2015 | 2015-09-30 | 13.43% | +15.86 pp |
| Q2 2015 | 2015-06-30 | 11.22% | −2.22 pp |
| Q1 2015 | 2015-03-31 | 14.78% | +160.09 pp |
| Q4 2014 | 2014-12-31 | 17.31% | +125.13 pp |
| Q3 2014 | 2014-09-30 | −2.43% | +1348.00 pp |
| Q2 2014 | 2014-06-30 | 13.44% | +5463.62 pp |
| Q1 2014 | 2014-03-31 | −145.30% | +11926.81 pp |
| Q4 2013 | 2013-12-31 | −107.82% | +1041.08 pp |
| Q3 2013 | 2013-09-30 | −1,350.44% | +11922.09 pp |
| Q2 2013 | 2013-06-30 | −5,450.18% | +4488.28 pp |
| Q1 2013 | 2013-03-31 | −12,072.11% | −8392.78 pp |
| Q4 2012 | 2012-12-31 | −1,148.90% | +22696.34 pp |
| Q3 2012 | 2012-09-30 | −13,272.53% | +74827.47 pp |
| Q2 2012 | 2012-06-30 | −9,938.46% | −8848.19 pp |
| Q1 2012 | 2012-03-31 | −3,679.33% | — |
| Q4 2011 | 2011-12-31 | −23,845.24% | — |
| Q3 2011 | 2011-09-30 | −88,100.00% | — |
| Q2 2011 | 2011-06-30 | −1,090.27% | — |
Supernus Pharmaceuticals ebitda margin trends
Over the last five fiscal years, Supernus Pharmaceuticals's ebitda margin decreased from 36.86% to 4.07%, a change of −32.79 percentage points. The latest reported quarter, Q2 2026, shows −26.28%.
About the metric
What EBITDA margin means
EBITDA margin measures EBITDA as a percentage of revenue. It can help compare operating profitability over time, but it excludes capital intensity, financing costs, taxes, and other items and is generally unsuitable for financial companies.
Calculation and source
How EBITDA margin is calculated
TickerStat calculates EBITDA margin as EBITDA divided by positive reported revenue for the same fiscal period. Changes are shown in percentage points. Fiscal periods can differ from calendar years, so exact period-end dates are included.
Review Supernus Pharmaceuticals source filings ↗Community posts
Supernus and Indivior report sales growth ahead of their expected merger closing
Supernus ($SUPN) reported third-quarter 2026 revenue of $226.8 million, up 18%, with Qelbree sales increasing 12% to $90.8 million and Onapgo contributing $17.1 million. Separately, merger partner Indivior ($INDV) posted revenue of $356 mil ...
Supernus confirms ONAPGO exclusivity and seeks a second supplier
Supernus ($SUPN) said the FDA has recognized orphan-drug exclusivity for ONAPGO, its apomorphine infusion treatment for motor fluctuations in adults with advanced Parkinson's disease. The seven-year protection period runs from the medicine' ...
